UCLA researchers developed AlloCAR70-NKT, an allogeneic cell therapy engineered to combat metastatic renal cell carcinoma. This innovative immunotherapy utilizes CD70-directed CAR-engineered natural killer T cells designed to attack tumors and reprogram the tumor microenvironment without requiring patient-specific customization. Preclinical mouse models demonstrated robust tumor targeting and a favorable safety profile. This off-the-shelf therapy could reduce manufacturing delays and broaden accessibility for patients with advanced kidney cancer, addressing unmet clinical needs.